XTX Topco’s G1 Therapeutics GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-21,020
Closed -$47.9K – 2737
2024
Q2
$47.9K Buy
21,020
+10,718
+104% +$40.9K ﹤0.01% 1516
2024
Q1
$44.5K Sell
10,302
-146,899
-93% -$512K 0.01% 1486
2023
Q4
$479K Sell
157,201
-139,400
-47% -$262K 0.11% 286
2023
Q3
$427K Buy
296,601
+186,753
+170% +$361K 0.07% 490
2023
Q2
$274K Sell
109,848
-184,444
-63% -$504K 0.05% 782
2023
Q1
$789K Buy
294,292
+192,010
+188% +$923K 0.17% 99
2022
Q4
$555K Buy
102,282
+87,345
+585% +$732K 0.12% 255
2022
Q3
$187K Sell
14,937
-30,619
-67% -$350K 0.05% 806
2022
Q2
$225K Buy
+45,556
New +$252K 0.09% 419

XTX Topco's GTHX Position: Q3 2024 in Review

XTX Topco sold out of G1 Therapeutics (GTHX) in Q3 2024, closing a stake of 21,020 shares — an estimated $47.9K sold.

XTX Topco first reported a position in GTHX in Q2 2022 and held it in 9 quarters. The position peaked at $789K in Q1 2023. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • XTX Topco reported no remaining G1 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • XTX Topco sold 21,020 G1 Therapeutics shares in Q3 2024, an estimated $47.9K.
  • XTX Topco first reported a position in G1 Therapeutics in Q2 2022 and held it in 9 quarters.
  • XTX Topco's G1 Therapeutics position peaked at $789K in Q1 2023.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics as of Q3 2024.

Based on XTX Topco's 13F filing for Q3 2024, filed 14 Nov 2024.